Evaluation of effectiveness of pain control in patients after total hip replacement using the anaesthetic continuous-infusion device with bupivacaine

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
03/03/2007		☐ Protocol		
Registration date 13/04/2007	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	Individual participant data		
09/05/2019	Musculoskeletal Diseases			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Dave Weichih Chen

Contact details

Orthopaedic Department Chang Gung Memorial Hospital Taipei-Linkou Medical Center 5 Fu-Shing St., Kweishan Taoyuan Taiwan 333

achih121@ms75.hinet.net

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Evaluation of effectiveness of pain control in patients after total hip replacement using the anaesthetic continuous-infusion device with bupivacaine

Study objectives

The Anaesthetic Continuous-Infusion Device (ACID) with bupivacaine is effective for post-Total Hip Replacement (THA) pain control.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received from the Institutional Review Board of the Chang Gung Memorial Hospital on the 25th December 2006 (ref: 95-1192B).

Study design

Rrandomised double-blind placebo-controlled study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Osteoarthritic hip

Interventions

Group I (25 patients): ACID intra-articular (above lessor trochanter) and normal saline 100 ml Group II (25 patients): ACID inter-muscular (between tensor facia lata and gluteal medius) and normal saline 100 ml

Group III (25 patients): ACID intra-articular (above lessor trochanter) and bupivacaine 0.5% 100 ml

Group IV (25 patients): ACID intra-articular (between tensor facia lata and gluteal medius) and bupivacaine 0.5%100 ml

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Bupivacaine

Primary outcome measure

Pain control

Secondary outcome measures

Improve post-operative hip function and rehabilitation programs

Overall study start date

01/08/2007

Completion date

31/07/2009

Eligibility

Key inclusion criteria

Consecutive 100 patients with indications for total hip replacement.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

100 patients

Total final enrolment

92

Key exclusion criteria

Patients who refuse to join the clinical trial.

Date of first enrolment

01/08/2007

Date of final enrolment

31/07/2009

Locations

Countries of recruitment

Taiwan

Study participating centre Orthopaedic Department

Taoyuan Taiwan 333

Sponsor information

Organisation

Republic of China National Science Council (Taiwan)

Sponsor details

106 Ho-Ping East Road Section 2 Taipei Taiwan 106

Sponsor type

Government

ROR

https://ror.org/02kv4zf79

Funder(s)

Funder type

Government

Funder Name

Republic of China National Science Council (Taiwan)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2010	09/05/2019	Yes	No